To review the pharmacology, pharmacokinetics, clinical efficacy, and safety profile of long-acting (LA) risperidone for the treatment of schizophrenia.
DATA SOURCES
Information was selected from PubMed (1965–July 2004). Applicable scientific posters were also used.
STUDY SELECTION AND DATA EXTRACTION
All published information on risperidone LA was considered. Material providing a comprehensive description was considered.
DATA SYNTHESIS
Risperidone LA is the first long-acting, injectable atypical antipsychotic. It is dosed at 25–50 mg every 2 weeks. Adverse effects are similar to those seen with oral risperidone. A short-term study showed that risperidone LA is better than placebo in reducing the signs and symptoms of schizophrenia, and a long-term trial showed that stable schizophrenic patients can be switched from either oral or other injectable antipsychotic medications to risperidone LA.
CONCLUSIONS
Risperidone LA is efficacious and safe in the treatment of schizophrenia.
. RobinsonD, WoernerMG, AlvirJM, BilderR, GoldmanR, GeislerS, Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry1999; 56: 241–7.
2.
. DavisJM. Overview. Maintenance therapy in psychiatry, 1: schizophrenia. Am J Psychiatry1975; 132: 1237–45.
3.
. SchoolerNR, KeithSJ, SevereJB, MatthewsSM, BellackAS, GlickID. Relapse and rehospitalization during maintenance treatment of schizophrenia. Arch Gen Psychiatry1997; 54: 453–64.
4.
. MarderSR, DavisJM, ChouinardG. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J Clin Psychiatry1997; 58: 538–46.
5.
. MooreDB, KellyDL, SherrJD, LoveRC, ConleyRR. Rehospitalization rates for depot antipsychotics and pharmacoeconomic implications: comparison with risperidone. Am J Health Syst Pharm1998; 55: 17–9.
6.
. LasserRA, RamstackJM, GrandolfiGP, MannaertE, HoorePD. Long-acting injectable risperidone [Risperdal Consta]: manufactured using Medisorb microsphere technology, pharmacokinetics, and injection site assessments (poster). Presented at: International Congress of Schizophrenia Research, Colorado Springs, CO, March 29–April 2, 2003.
. HeykantsJ, HuangML, MannensG, MeuldermansW, SnoechE, Van BeijsterveldtL. The pharmacokinetics of risperidone in humans: a summary. J Clin Psychiatry1994; 55: 13–7.
9.
. Diagnostic and statistical manual of mental disorders. 4th revision. Washington, DC: American Psychiatric Association, 1994.
10.
. KaneJM, EerdekensM, LindenmayerJP, KeithSJ, LesemM, KarcherK. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry2003; 160: 1125–32.
11.
. FleischhackerWW, EerdekensM, KancherK, RemingtonG, LlorcaPM, ChrzanowskiW, Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic. J Clin Psychiatry2003; 64: 1250–7.
12.
. SchoolerNR. Relapse and rehospitalization: comparing oral and depot antispsychotics. J Clin Psychiatry2003; 64 (suppl 16): 14–7.
13.
. ChueP, EerdekensM, AugustynsI, LachauxB, MolcanP, ErikssonL, Efficacy and safety of long-acting risperidone microspheres and risperidone oral tablets (poster). Presented at: 11th Biennial Winter Workshop on Schizophrenia, Davos, Switzerland, February 24–March 1, 2002.
14.
. TurnerM, EerdekensM, JackoM, EerdekensE. Long-acting injectable risperidone: safety and efficacy in stable patients switched from conventional depot antipsychotics. Int Clin Psychopharmacol2004; 19: 241–9.
15.
. KaneJ, GharabawiG, BossieCA, ZhuY, LasserRA. Effect of a novel long-acting antipsychotic formulation in stable patients with schizoaffective disorder (poster). Presented at: 41st Annual American College of Neuropsychopharmacology, San Juan, Puerto Rico, December 8–12, 2002.
16.
. CanusoC, BossieC, ZhuY, LasserR, FalkaiP. Long-acting risperidone reduces symptoms of depression and anxiety in stable patients with schizophrenia and schizoaffective disorder (poster). Presented at: 5th Annual International Congress on Bipolar Disorder, Pittsburgh, PA, June 12–14, 2003.
17.
. LasserR, Kosik-GonzalezC, BossieC, GharabawiG. Long-term treatment of bipolar disorder: consideration of the current state and future directions (poster). Presented at: 5th Annual International Congress on Bipolar Disorder, Pittsburgh, PA, June 12–14, 2003.
18.
. MarderSR, ConleyR, EreshefskyL, KaneJM, TurnerMS. Dosing and switching strategies for long-acting risperidone. J Clin Psychiatry2003; 64 (suppl 16): 41–6.
19.
. JesteDV, OkamotoA, NapolitanoJ, KaneJM, MartinexRA. Low incidence of persistent tardive dyskinesia in elderly patients with dementia treated with risperidone. Am J Psychiatry2000; 157: 1150–5.
20.
. BossieCA, LasserRA, GharabawiG. Low or absent pain and injectable site effects with long-acting risperidone (poster). Presented at: 156th Annual American Psychiatric Association Meeting, San Francisco, May 17–22, 2003.
21.
. CanusoCM, BossieCA, LasserRA, GharabawiG. Reduced serum prolactin levels after treatment with long-acting risperidone (poster). Presented at: 156th Annual American Psychiatric Association Meeting, San Francisco, May 17–22, 2003.
22.
. KleinbergDL, DavisJM, Van BaelenB, BrecherM. Prolactin levels and adverse events in patients treated with risperidone. J Clin Psychopharmacol1999; 19: 57–61.
23.
. CsernanskyJG, MahmoudR, BrennerR. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med2002; 346: 16–22.
24.
. NasrallahHA, DuchesneI, MehnertA, JanagapC. Long-acting risperidone injection improves quality of life. J Clin Psych2004; 65 (4): 531–6.
25.
. RemingtonG, DevosE, EerdekensM, DuchesneI, LealA, MehnertA. Treatment with long-acting risperidone injection reduces healthcare resource use (poster). Presented at: 13th Annual Collegium Internationale Neuro-Psychopharmacologicum Congress, Montreal, Canada, June 23–27, 2002.
. 2004 Drug topics red book. Montvale, NJ: Thompson PDR, 2004.
28.
. LasserRA, BossieCA, GharabawiGM, TurnerM. Patients with schizophrenia previously stabilized on conventional depot antipsychotics experience significant clinical improvements following treatment with long-acting risperidone. Eur Psychiatry2004; 19: 219–25.
29.
. Van osJ, BossieCA, LaserRA. Improvements in stable patients with psychotic disorders switched from oral conventional antipsychotics therapy to long-acting risperidone. Int Clin Psychopharmacol2004; 19: 229–32.
